Local environment

Our research unit is based on close collaborations with several structures and biotechs. hosted on our premises.

Hospital environment

 

 The center for familial amyloid neuropathies and other rare peripheral neuropathies (NNERF) provides comprehensive management of these diseases, by improving access to diagnosis, offering the best treatment and ensuring patient information and training. and his family.

Research institute

 

 

The Baulieu Institute is evaluating the modulating and potentially protective role of the FKBP52 protein in senile dementias (TAUopathies, including Alzheimer’s disease). He also assesses the synaptic damage associated with Alzheimer’s disease and various therapeutic approaches to correct it.

Biotechnology companies

 

 

CryoCapCell is developing an innovative technology to perform multimodal microscopic imaging analyses, with a particular focus on CLEM correlative microscopy, which combines light and electron microscopy.

 

 

Most pathologies of the nervous system do not currently have effective treatments. MAAsiRNA is dedicated to the development of targeted therapy based on interfering RNA (siRNA). After more than a decade of research in our laboratory, we have developed an siRNA-based treatment for the world’s most common inherited peripheral neuropathy, Charcot-Marie-Tooth disease type 1A (CMT1A). CMT1A affects one in 5,000 people, totaling 1.5 million people worldwide. Our current goal is to progress toward a therapy that can be administered to patients.

 

 

Mapreg stimulates microtubule dynamics to rescue neuronal function in the context of traumatic brain injury, psychiatric diseases, neurodegenerative diseases, and strokes.